Brown AN - Search Results

1

Why Molnupiravir Fails in Hospitalized Patients.

Brown AN, Lang Y, Zhou J, Franco EJ, Hanrahan KC, Bulitta JB, Drusano GL. Brown AN, et al. mBio. 2022 Dec 20;13(6):e0291622. doi: 10.1128/mbio.02916-22. Epub 2022 Nov 14. mBio. 2022. PMID: 36374076 Free PMC article.

2

Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.

McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL. McSharry JJ, et al. Antimicrob Agents Chemother. 2009 Jun;53(6):2375-81. doi: 10.1128/AAC.00167-09. Epub 2009 Apr 13. Antimicrob Agents Chemother. 2009. PMID: 19364864 Free PMC article.

3

In vitro system for modeling influenza A virus resistance under drug pressure.

Brown AN, McSharry JJ, Weng Q, Driebe EM, Engelthaler DM, Sheff K, Keim PS, Nguyen J, Drusano GL. Brown AN, et al. Antimicrob Agents Chemother. 2010 Aug;54(8):3442-50. doi: 10.1128/AAC.01385-09. Epub 2010 May 24. Antimicrob Agents Chemother. 2010. PMID: 20498316 Free PMC article.

4

Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.

Brown AN, Bulitta JB, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL. Brown AN, et al. Antimicrob Agents Chemother. 2011 Apr;55(4):1747-53. doi: 10.1128/AAC.01629-10. Epub 2011 Jan 24. Antimicrob Agents Chemother. 2011. PMID: 21263045 Free PMC article.

5

Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.

Brown AN, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL. Brown AN, et al. Antimicrob Agents Chemother. 2011 Apr;55(4):1740-6. doi: 10.1128/AAC.01628-10. Epub 2011 Jan 24. Antimicrob Agents Chemother. 2011. PMID: 21263046 Free PMC article.

6

Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.

Brown AN, McSharry JJ, Adams JR, Kulawy R, Barnard RJ, Newhard W, Corbin A, Hazuda DJ, Louie A, Drusano GL. Brown AN, et al. Antimicrob Agents Chemother. 2012 Mar;56(3):1170-81. doi: 10.1128/AAC.05383-11. Epub 2011 Dec 12. Antimicrob Agents Chemother. 2012. PMID: 22155837 Free PMC article.

7

Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.

Brown AN, Adams JR, Baluya DL, Drusano GL. Brown AN, et al. Antimicrob Agents Chemother. 2015 Jul;59(7):3771-7. doi: 10.1128/AAC.00469-15. Epub 2015 Apr 13. Antimicrob Agents Chemother. 2015. PMID: 25870053 Free PMC article.

8

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.

Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, Brown DL, Kwara A, Mirsalis JC, Hafner R, Louie A. Brown AN, et al. Among authors: brown dl. mBio. 2015 Nov 3;6(6):e01741-15. doi: 10.1128/mBio.01741-15. mBio. 2015. PMID: 26530386 Free PMC article.

9

Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a.

Gallegos KM, Drusano GL, D Argenio DZ, Brown AN. Gallegos KM, et al. Among authors: brown an. J Infect Dis. 2016 Oct 15;214(8):1192-7. doi: 10.1093/infdis/jiw358. Epub 2016 Aug 5. J Infect Dis. 2016. PMID: 27496974 Free PMC article.

10

Reply to Scagnolari et al.

Brown AN, Gallegos KM, D'Argenio DZ, Drusano GL. Brown AN, et al. J Infect Dis. 2017 Feb 1;215(3):493-494. doi: 10.1093/infdis/jiw580. J Infect Dis. 2017. PMID: 28003357 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page